Tharimmune (THAR) said Monday it plans to initiate a phase 2 study that will evaluate TH104 in reducing itch in patients with primary biliary cholangitis, a rare, chronic liver disease.
The clinical trial, expected to begin in 2025, follows results from a phase 1 study and recent regulatory feedback from the European Medicines Agency and the US Food and Drug Administration, the biotechnology company said.
Preliminary results from the trial, which has a planned enrollment of 40 patients, are expected in late 2025, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。